Earlier studies have shown that FAK deficiency significantly suppresses MET/CAT-driven hepatocarcinogenesis (37), In DUSP22-deficient tumors, FAK activation promotes the progression of nonalcoholic steatohepatitis–associated HCC. Here, PTK2 is linked to metabolic dysfunction-associated steatohepatitis.